Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marcus Schuchmann

Showing results (51-60 of 85) with videos related to

Pageof 9
Sort By:
Journal of Clinical Gastroenterology|July 12, 2014
Predictive scores in primary biliary cirrhosis: a retrospective single center analysis of 204 patientsArndt Weinmann, Thomas Sattler, Hans-Peter Unold, et al.
Immunity|August 20, 2013
Interleukin-33-dependent innate lymphoid cells mediate hepatic fibrosisTamar McHedlidze, Maximilian Waldner, Steffen Zopf, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|November 28, 2012
The impact of patient and tumour baseline characteristics on the overall survival of patients with advanced hepatocellular carcinoma treated with sorafenibMarcus A Wörns, Sandra Koch, Ina M Niederle, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|October 16, 2013
Defer or treat? Reasons for treatment decisions in patients with chronic hepatitis C genotype 1 in the early era of directly acting antiviral agentsJens M Kittner, Nora M Weiss, Jörg Wiltink, et al.
European Journal of Internal Medicine|May 17, 2011
Alterations in lipid, carbohydrate and iron metabolism in patients with non-alcoholic steatohepatitis (NASH) and metabolic syndromeAnca Zimmermann, Tim Zimmermann, Jörn Schattenberg, et al.
International Journal of Oncology|November 27, 2010
Down-regulation of CYLD as a trigger for NF-κB activation and a mechanism of apoptotic resistance in hepatocellular carcinoma cellsToni Urbanik, Bruno Christian Köhler, Regina Johanna Boger, et al.
Transplant International : Official Journal of the European Society for Organ Transplantation|November 7, 2012
Metabolic syndrome and its association with fatty liver disease after orthotopic liver transplantationMartin F Sprinzl, Arndt Weinmann, Nikola Lohse, et al.
Journal of Hepatology|June 26, 2012
Liver specific deletion of CYLDexon7/8 induces severe biliary damage, fibrosis and increases hepatocarcinogenesis in miceToni Urbanik, Regina Johanna Boger, Thomas Longerich, et al.
Journal of Clinical Gastroenterology|February 28, 2009
Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosisMarcus Alexander Wörns, Arndt Weinmann, Kerstin Pfingst, et al.
Journal of Hepatology|June 28, 2011
Ablation of c-FLIP in hepatocytes enhances death-receptor mediated apoptosis and toxic liver injury in vivoJörn M Schattenberg, Tim Zimmermann, Marcus Wörns, et al.
Pageof 9

Showing results (51-60 of 85) with videos related to

Sort By:
Pageof 9
Journal of Clinical Gastroenterology|July 12, 2014
Predictive scores in primary biliary cirrhosis: a retrospective single center analysis of 204 patientsArndt Weinmann, Thomas Sattler, Hans-Peter Unold, et al.
Immunity|August 20, 2013
Interleukin-33-dependent innate lymphoid cells mediate hepatic fibrosisTamar McHedlidze, Maximilian Waldner, Steffen Zopf, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|November 28, 2012
The impact of patient and tumour baseline characteristics on the overall survival of patients with advanced hepatocellular carcinoma treated with sorafenibMarcus A Wörns, Sandra Koch, Ina M Niederle, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|October 16, 2013
Defer or treat? Reasons for treatment decisions in patients with chronic hepatitis C genotype 1 in the early era of directly acting antiviral agentsJens M Kittner, Nora M Weiss, Jörg Wiltink, et al.
European Journal of Internal Medicine|May 17, 2011
Alterations in lipid, carbohydrate and iron metabolism in patients with non-alcoholic steatohepatitis (NASH) and metabolic syndromeAnca Zimmermann, Tim Zimmermann, Jörn Schattenberg, et al.
International Journal of Oncology|November 27, 2010
Down-regulation of CYLD as a trigger for NF-κB activation and a mechanism of apoptotic resistance in hepatocellular carcinoma cellsToni Urbanik, Bruno Christian Köhler, Regina Johanna Boger, et al.
Transplant International : Official Journal of the European Society for Organ Transplantation|November 7, 2012
Metabolic syndrome and its association with fatty liver disease after orthotopic liver transplantationMartin F Sprinzl, Arndt Weinmann, Nikola Lohse, et al.
Journal of Hepatology|June 26, 2012
Liver specific deletion of CYLDexon7/8 induces severe biliary damage, fibrosis and increases hepatocarcinogenesis in miceToni Urbanik, Regina Johanna Boger, Thomas Longerich, et al.
Journal of Clinical Gastroenterology|February 28, 2009
Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosisMarcus Alexander Wörns, Arndt Weinmann, Kerstin Pfingst, et al.
Journal of Hepatology|June 28, 2011
Ablation of c-FLIP in hepatocytes enhances death-receptor mediated apoptosis and toxic liver injury in vivoJörn M Schattenberg, Tim Zimmermann, Marcus Wörns, et al.
Pageof 9